Press release content from Business Wire. The AP news staff was not involved in its creation.

Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 4, 2023 GMT

FOXBOROUGH, Mass.--(BUSINESS WIRE)--Jan 4, 2023--

Suono Bio, the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, today announced the first patient has been dosed with its SuonoCalm TM product. This next-generation treatment leverages the company’s ultrasonic platform for topical and oral delivery of therapeutics to the gastrointestinal tract, including biologics and genetic medicines.

“We are ecstatic to witness our foundational technology implemented in humans for the first time. This has been years in the making and puts us much closer to our goal of dramatically improving treatment options for serious gastrointestinal diseases and beyond,” said Scott Kellogg, Chief Executive Officer of Suono Bio.

“Since we first discovered the ability to deliver unformulated therapeutics, including RNA-based medicines, to the GI tract, the company has worked diligently to de-risk this technology and build out a meaningful pipeline of therapeutic candidates. The initiation of clinical testing begins a new phase for the company and helps serve to prove out not only the SuonoCalm TM, but the broader platform for enabling the oral delivery of biologics and other delicate medicines, the holy grail in drug delivery,” added Professor Robert Langer, co-founder and director of Suono Bio.”


The SuonoCalm is a therapeutic platform for the ultra-rapid administration of a wide range of medicines. The technology is being tested for the topical administration of mesalamine for the treatment of ulcerative colitis and represents Suono Bio’s lead indication. The trial is assessing the safety and tolerability of the treatment, including tissue-level drug concentrations, to inform final treatment protocols. “We are excited to be leading the first-in-human testing of this new technology, both for its potential promise to address unmet needs for patients with IBD and broader potential impact on GI health,” added Dr. Jake Begun IBD Group Leader at Mater Research University, and Suono Bio Medical Advisory Board member.

About Suono Bio

Suono Bio is a clinical-stage company developing novel treatment options to enable the topical and oral delivery of biologics and genetic medicines in a formulation-independent manner. Suono Bio’s platform was developed at The Massachusetts Institute of Technology in Professor Robert Langer’s laboratory and enables rapid, delivery of a wide-range of therapeutic payloads. For more information, please visit


View source version on

CONTACT: Investor and Media Inquiries



SOURCE: Suono Bio

Copyright Business Wire 2023.

PUB: 01/04/2023 09:50 AM/DISC: 01/04/2023 09:51 AM